Fulcrum Therapeutics (FULC) Receivables - Other (2020 - 2025)
Fulcrum Therapeutics (FULC) has disclosed Receivables - Other for 6 consecutive years, with $979000.0 as the latest value for Q1 2025.
- On a quarterly basis, Receivables - Other changed N/A to $979000.0 in Q1 2025 year-over-year; TTM through Mar 2025 was $979000.0, a N/A change, with the full-year FY2024 number at $2.1 million, up 290.32% from a year prior.
- Receivables - Other was $979000.0 for Q1 2025 at Fulcrum Therapeutics, down from $2.1 million in the prior quarter.
- In the past five years, Receivables - Other ranged from a high of $3.7 million in Q3 2024 to a low of $99000.0 in Q1 2023.
- A 5-year average of $1.1 million and a median of $766500.0 in 2022 define the central range for Receivables - Other.
- Peak YoY movement for Receivables - Other: tumbled 87.66% in 2023, then skyrocketed 530.34% in 2024.
- Fulcrum Therapeutics' Receivables - Other stood at $1.1 million in 2021, then tumbled by 79.86% to $229000.0 in 2022, then skyrocketed by 134.5% to $537000.0 in 2023, then surged by 290.32% to $2.1 million in 2024, then crashed by 53.29% to $979000.0 in 2025.
- Per Business Quant, the three most recent readings for FULC's Receivables - Other are $979000.0 (Q1 2025), $2.1 million (Q4 2024), and $3.7 million (Q3 2024).